What the FDA labels say about taking them together
Dihydroergotamine and naratriptan
Naratriptan's FDA label of October 30, 2025 names dihydroergotamine in its contraindications section; the dihydroergotamine labels PlainMeds reads (4) do not name naratriptan. The naratriptan label: “Because these effects may be additive, use of ergotamine-containing or ergot-type medications and naratriptan within 24 hours of each other is contraindicated.”
Check it at the source: the dihydroergotamine FDA label on DailyMed (effective March 6, 2025, Oceanside Pharmaceuticals); the naratriptan FDA label on DailyMed (effective October 30, 2025, Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.).
What does the dihydroergotamine label say about naratriptan?
Dihydroergotamine's label (effective March 6, 2025) and its 3 other brand-application labels do not name naratriptan in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Dihydroergotamine Mesylate), NDA020148 (Bausch), as published by Oceanside Pharmaceuticals, effective March 6, 2025 (SPL set 977de209-c53a-4cb4-9f3f-1e850600a9dc), via openFDA; the full label on DailyMed
What does the naratriptan label say about dihydroergotamine?
Naratriptan label, contraindications… disease [see Warnings and Precautions (5.5) ] Uncontrolled hypertension [see Warnings and Precautions (5.8) ] Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions ( 7.1 , 7.2 )] Hypersensitivity to naratriptan (angioedema and anaphylaxis seen) [see Warnings and Precautions (5.9) ] Severe renal or hepatic impairment [see Use in Specific Populations ( 8.6 , 8.7 ), Clinical Pharmacology (12.3) ] History of coronary artery disease or coronary artery vasospasm ( 4 ) Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders ( 4 ) History …
Naratriptan label, drug interactionsBecause these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours of each other is contraindicated.
Source: FDA drug label (naratriptan), Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc., effective October 30, 2025 (SPL set 41c29652-32f8-48dc-9038-0e2195aa2084), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Dihydroergotamine | Naratriptan | |
|---|---|---|
| Labeled for | Migraine | Migraine |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $29.44 per mL 4 mg/mL nasal spray | $1.08 per tablet 2.5 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once